Standout Papers
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK (2009)
- Unique Clinicopathologic Features Characterize ALK -Rearranged Lung Adenocarcinoma in the Western Population (2009)
- ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer (2013)
- Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma (2018)
Immediate Impact
3 by Nobel laureates 16 from Science/Nature 138 standout
Citing Papers
Radiotherapy toxicities: mechanisms, management, and future directions
2025 Standout
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
2022 Standout
Works of Beow Y. Yeap being referenced
Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non–Small Cell Lung Cancer
2018
Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib
2006
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Beow Y. Yeap | 10059 | 6993 | 1270 | 3028 | 203 | 14.1k | |
| George R. Blumenschein | 4981 | 6894 | 1155 | 2671 | 324 | 11.7k | |
| Keyue Ding | 8204 | 7933 | 1614 | 3311 | 214 | 14.2k | |
| Thierry Le Chevalier | 9812 | 8049 | 1334 | 3570 | 243 | 15.2k | |
| Alan Horwich | 5490 | 2585 | 2322 | 1926 | 136 | 10.1k | |
| Johan Vansteenkiste | 12892 | 12602 | 1027 | 4267 | 167 | 18.0k | |
| Keith M. Kerr | 10917 | 9456 | 1327 | 3253 | 180 | 16.9k | |
| Paul M. Harari | 7072 | 8412 | 3911 | 4652 | 300 | 17.7k | |
| David Raben | 5462 | 6676 | 3585 | 4350 | 234 | 14.9k | |
| Michele Reni | 2957 | 5956 | 1646 | 1964 | 316 | 11.1k | |
| Rolf A. Stahel | 6651 | 5625 | 923 | 4413 | 322 | 13.8k |
All Works
Loading papers...